Hims & Hers Health Shares Tumble as its Weight-Loss Treatments Face Tough Environment
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in the space is a decision by drugmaker Eli Lilly on Tuesday to cut prices of Zepbound, another weight-loss drug.
Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.
Shares of Hims & Hers Health Inc (NYSE: HIMS) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m ...
Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback